Nzyme, a Spanish personal fairness fund backed by Kibo Ventures, has introduced its ultimate closing at €160 million to put money into Spanish firms working in extremely fragmented B2B sectors, with a concentrate on conventional companies which have robust transformation potential by way of the adoption of expertise and sector consolidation.
The fund has attracted assist from a various base of buyers, together with the dedication of CDTI by way of its SICC Innvierte, in addition to Spanish enterprise households, profitable entrepreneurs who establish with the fund’s technique, banks, and worldwide household workplaces with pursuits in Spain.
Vicente Vázquez, Managing Director at Nzyme, stated: “The profitable closing of this fund, in a difficult atmosphere, confirms buyers’ confidence within the Nzyme workforce, our technique, and the potential of Spanish SMEs to remodel and develop. We’re satisfied that by combining enterprise consolidation with technological innovation, we are able to create robust leaders in conventional and fragmented sectors.
“We stay dedicated to producing sustainable worth and contributing to the nation’s financial improvement by way of strategic investments and a detailed, hands-on method with the businesses.”
Nzyme is the newest enterprise capital fund launched by Kibo Ventures, with the mission to catalyse the transformation of the businesses and industries through which it invests. Kibo Ventures is a VC agency was based in 2012 to empower modern European tech entrepreneurs to sort out important challenges and obtain progress by constructing world firms.
Nzyme prioritises funding in service and software program firms inside fragmented industries, characterised by their potential to generate worth by way of sustainability and expertise.
Moreover, Nzyme’s administration workforce is made up of execs with expertise in personal fairness, expertise, and enterprise transformation, together with Fernando Díaz Solís, Vicente Vázquez Bouza, José Manuel Gasalla, Juan López Santamaría, and Pablo Campos, supported by the Kibo Ventures community.
Moreover, the fund has Oliver Wyman as a strategic advisor, which permits Nzyme to entry superior sector analyses, channel proprietary alternatives, and facilitate the internationalisation of the businesses in its portfolio.
The fund has already made its first investments, together with a notable entry into healthcare distribution, built-in into Kuma Group, in addition to a number of investments in skilled companies firms. These transactions are a part of Nzyme’s strategic venture to construct trade leaders by way of consolidation and technological innovation in fragmented sectors.
As well as, the fund has superior plans to combine different firms that may additional strengthen the expansion of its portfolio.
In April 2025, Nzyme accomplished the divestment of Kuma’s dental division, lower than two years after its acquisition, reaffirming its skill to create worth by way of energetic transformation and progress methods.
The fund explains that they make investments with “a prudent and hands-on method, specializing in well-managed firms with strong buildings, supporting them of their enlargement processes“. The fund prioritizes shut collaboration with Founders and administration groups to facilitate institutionalisation, generational shift, and internationalisation.
The target is to assist firms which have confirmed their value of their native markets, a lot of them situated exterior main city facilities, in scaling up, professionalising, and successfully adopting expertise. On this course of, the fund offers key assist in one of the advanced challenges of enterprise progress: transitioning from buildings of 20–40 workers to organisations of over 150 folks, with scalable processes, built-in expertise, and worldwide ambition.
Nzyme targets firms with EBITDA beginning at roughly €1 million or round 20 workers as a place to begin to construct sector platforms. The fund anticipates a portfolio of 8 to 10 platforms, making particular person investments of between €15 and €20 million by way of the acquisition and integration of a number of firms.
The technique combines inorganic progress with the adoption of superior applied sciences – reminiscent of AI, huge information, machine studying, IoT, edge computing, and cloud – to drive operational effectivity, scalability, and aggressive differentiation.
With an energetic method, the fund applies the traditional personal fairness levers – administration succession, institutionalisation, and worldwide enlargement – integrating expertise as a driver of sustainable progress and worth creation.
